Dianthus Therapeutics Inc

Investors Eye Dianthus Therapeutics After TD Cowen Buy Rating & Phase 3 CAPTIVATE Go‑Decision

Explore how Dianthus Therapeutics’ Phase‑3 CAPTIVATE trial and TD Cowen’s buy rating could reshape its stock, pipeline and profitability outlook.

Dianthus Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

09/03/2026, 20:44

3 minutes to read

Dianthus Therapeutics Completes Phase 2 Enrollment for Myasthenia Gravis Trial

Dianthus Therapeutics has completed enrollment for its Phase 2 trial of DNTH103 for Generalized Myasthenia Gravis, with top-line results expected in September.

Dianthus Therapeutics Inc
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

12/05/2025, 22:23

2 minutes to read